Emmanuelle Waubant, Ph.D., M.D.

Neurologist

Dr. Emmanuelle Waubant is a neurologist and specialist in the treatment of patients with multiple sclerosis (MS). A native of France, she earned her medical degree at the University of Medicine in Lille, France, and completed her residency and chief residency at Toulouse University Hospital. Waubant completed fellowships in neuroimmunology at UCSF Medical Center and in clinical neuroimmunology at UCSF's Multiple Sclerosis Center at Mount Zion. She then returned to France to head a clinical research center at the Pitie-Salpetriere University Hospital. After returning to UCSF, she joined the staff of UCSF's Multiple Sclerosis Center and is an assistant professor in neurology.

Clinics

UCSF Regional Pediatric Multiple Sclerosis Center
400 Parnassus Ave., 8th Floor
San Francisco, CA 94117
Phone: (415) 353-3939

Conditions & Treatments

More about Emmanuelle Waubant

Additional Languages

French

Education

University of Medicine, Lille, France 1992

Residencies

Purpan University Hospital, Neurology 1992

Fellowships

UCSF Medical Center, Neurology 1999

Selected Research and Publications

  1. Ayscue P, Haren KV, Sheriff H, Waubant E, Waldron P, Yagi S, Yen C, Clayton A, Padilla T, Pan C, Reichel J, Harriman K, Watt J, Sejvar J, Nix WA, Feikin D, Glaser C, Ek M. Acute flaccid paralysis with anterior myelitis - california, june 2012-june 2014. MMWR Morb Mortal Wkly Rep. 2014 Oct 10; 63(40):903-6.
  2. Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014 Aug 1.
  3. Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A, Crabtree E, Goodin D, Waubant E, McCulloch C. Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014 Sep 15; 344(1-2):80-7.
  4. Chitnis T, Waubant E. B-cell depletion in children with neuroimmunologic conditions: The learning curve. Neurology. 2014 Jul 8; 83(2):111-2.
  5. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15; 83(3):278-86.
  6. Kraus V, Lawson EF, Scheven Ev, Tihan T, Garza J, Nathan RG, Cordoro KM, Waubant E. Atypical cases of scleroderma en coup de sabre. J Child Neurol. 2014 May; 29(5):698-703.
  7. Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014 Jul; 51(1):114-8.
  8. Waubant E, Cross A. MS and related disorders: groundbreaking news. Lancet Neurol. 2014 Jan; 13(1):11-3.
  9. Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E. Association of multiple sclerosis susceptibility variants and early attack location in the CNS. PLoS One. 2013; 8(10):e75565.
  10. Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E. Multiple sclerosis susceptibility genes: associations with relapse severity and recovery. PLoS One. 2013; 8(10):e75416.
  11. Maghzi AH, Minagar A, Waubant E. Neuroprotection in multiple sclerosis: a therapeutic approach. CNS Drugs. 2013 Oct; 27(10):799-815.
  12. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013; 8(7):e66308.
  13. Van Haren K, Waubant E. Therapeutic advances in pediatric multiple sclerosis. J Pediatr. 2013 Sep; 163(3):631-7.
  14. Marcus JF, Waubant EL. Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist. 2013 Apr; 3(2):65-80.
  15. Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, Kornberg A, Krupp LB, Pohl D, Rostasy K, Tenembaum S, Waubant E, Wassmer E. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 2013 Mar 19; 80(12):1161-8.
  16. Lulu S, Waubant E. Humoral-targeted immunotherapies in multiple sclerosis. Neurotherapeutics. 2013 Jan; 10(1):34-43.
  17. McElroy JP, Krupp LB, Johnson BA, McCauley JL, Qi Z, Caillier SJ, Gourraud PA, Yu J, Nathanson L, Belman AL, Hauser SL, Waubant E, Hedges DJ, Oksenberg JR. Copy number variation in pediatric multiple sclerosis. Mult Scler. 2013 Jul; 19(8):1014-21.
  18. Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, James JA. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler. 2013 Jun; 19(7):891-5.
  19. Julian L, Serafin D, Charvet L, Ackerson J, Benedict R, Braaten E, Brown T, O'Donnell E, Parrish J, Preston T, Zaccariello M, Belman A, Chitnis T, Gorman M, Ness J, Patterson M, Rodriguez M, Waubant E, Weinstock-Guttman B, Yeh A, Krupp LB. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol. 2013 Jan; 28(1):102-7.
  20. Waubant E. Improving outcomes in multiple sclerosis through early diagnosis and effective management. Prim Care Companion CNS Disord. 2012; 14(5).

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.